1.乳腺癌侵袭转移及其耐药机制；

2.肿瘤早期分子诊断和靶向治疗。

杨谨, 女，48岁，医学博士，主任医师，教授，肿瘤学博士研究生导师, 西安交通大学第一医院肿瘤内科副主任，肿瘤学系副主任。

1993年毕业于西安医科大学临床医疗系，2000年获肿瘤学硕士学位，2006年获医学博士学位。2010年美国马里兰大学Marlene and Stewart Greenbaum 肿瘤中心研修。中国研究型医院学会乳腺癌专业委员会常委，中国研究型医院学会精准医学与肿瘤MDT专业委员会乳腺学组副主任委员，中国抗癌协会乳腺癌专业委员会青年委员，陕西省抗癌协会生物治疗专业委员会候任主任委员，陕西省抗癌协会肿瘤化疗专业委员会和综合治疗专业委员会副主任委员，陕西省抗癌协会乳腺癌专业委员会，肺癌专业委员会，癌痛专业委员会及老年肿瘤专业委员会常委，国家自然科学基金一审评委，《现代肿瘤杂志》中青年编委，国际杂志《BMC Cancer》《Tumor Biol》《Oncotarget and Therapy》特约审稿专家。近年发表论文50余篇，SCI收录40余篇，副主编、参编医学专著7部，主持国家自然科学基金面上项目3项，横向课题2项，主持陕西省自然科学基金和科技攻关项目各1项，其他市、校、院级科研课题3项，获得陕西省科技进步二等奖1项，陕西省高校科技进步二等奖2项，主持院级新医疗、新技术2项。

1.Angiomotin通过Hippo-YAP信号通路调控肾癌干细胞样特性的机制研究。No. 81572527。国家自然科学基金面上项目，42.0万元，2016.01-2020.12。（主持人）

2.Angiomotin在肾透明细胞癌中异常表达的分子机制及潜在的靶向治疗价值，No.8117217。国家自然科学基金面上项目，60.0万元，2012.01-2015.12。（主持人）

3.肾癌特异性蛋白标志物的筛选与血清免疫蛋白质谱的建立，No. 30753669。国家自然科学基金面上项目，29.0万元，2008.01-2010.12。（主持人）

4.Angiomotin与乳腺癌干细胞的关系。No.2015JM8406。陕西省自然科学基金，3万元，2016.01-2019.12。（主持人）

5.Angiomotin与乳腺癌内分泌耐药的关系及其作用机制。横向课题，10万元，2016.01-2019.12。（主持人）

6.Angiomotin在肾透明细胞癌中异常表达的分子机制。西安交通大学自由探索和自主创新项目。5.0万元，2012.01-2014,12。（主持人）

1. 细胞极性蛋白异常在乳腺癌恶性进程中的作用机制研究。陕西高等学校科学技术奖（二等奖）

2. 肾癌特异性蛋白标志物的筛选、异常表达的分子机制和潜在靶向治疗价值。陕西高等学校科学技术奖（二等奖）

3. Chen ZL, Yang J, Shen YW, Li ST, Wang X, Lv M, Wang BY, Li P, Zhao W, Qiu RY, Liu Y, Liu PJ, Yang J.AmotP130 regulates Rho GTPase and decreases breast cancer cell mobility.J Cell Mol Med. 2018;22(4):2390-2403.

4. Wang F, Dohogne Z, Yang J,.Predictors of breast cancer cell types and their prognostic power in breast cancer patients.BMC Genomics. 2018 13;19(1):137.

5. Li S, Wang X, Yang J, Lv M, Zhang X, Li C, Zhang L, Shen Y, Zhang X, Chen Z, Wang F, Wang X, Li D, Yi M, Yang J. Clinicopathological features and survival of early stage breast cancer in northwest China: A population-based retrospective study of 1287 patients.Thorac Cancer. 2018 ;9(1):10-18.

6. Shen Y, Quan J, Wang M, Li S, Yang J, Lv M, Chen Z, Zhang L, Zhao X, Yang J. Tumor vasculogenic mimicry formation as an unfavorable prognostic indicator in patients with breast cancer. Oncotarget. 2017, 7;8(34):56408-56416.

7. Chen Z, Yang J, Li S, Lv M, Shen Y, Wang B, Li P, Yi M, Zhao X, Zhang L, Wang L, Yang J.Invasive lobular carcinoma of the breast: A special histological type compared with invasive ductal carcinoma.PLoS One. 2017 ;12(9):e0182397.

8. Zhao W, Qiu R, Li P, Yang J.PIM1: a promising target in patients with triple-negative breast cancer.Med Oncol. 2017 ;34(8):142.

9. Lv M, Zhang X, Shen Y, Wang F, Yang J, Wang B, Chen Z, Li P, Zhang X, Li S, Yang J. Clinical analysis and prognosis of synchronous and metachronous multiple primary malignant tumors.Medicine (Baltimore). 2017 ;96(17):e6799.

10. Meng Lv, Yanwei Shen, Jiao Yang, Shuting Li, Biyuan Wang, Zheling Chen, Pan Li, Peijun Liu, Jin Yang. Angiomotin family members: oncogenes or tumor suppressors? International Journal of Biological Sciences. 2017 ;13(6):772-781.

11. Li S, Shen Y, Wang M, Yang J, Lv M, Li P, Chen Z, Yang J. Loss of PTEN expression in breast cancer: association with clinicopathological characteristics and prognosis.Oncotarget. 2017 9;8(19):32043-32054.

12. Wang B, Yang J, Li S, Lv M, Chen Z, Li E, Yi M, Yang J. Tumor location as a novel high risk parameter for stage II colorectal cancers.PLoS One. 2017,23;12(6):e0179910.

13. Yang J, Li S, Lv M, Wu Y, Chen Z, Shen Y, Wang B, Chen L, Yi M, Yang J.Risk of subsequent primary malignancies among patients with prior colorectal cancer: a population-based cohort study. Onco Targets Ther. 2017 ,13;10:1535-1548.

14. Yang J, Du XL, Li S, Wu Y, Lv M, Dong D, Zhang L, Chen Z, Wang B, Wang F, Shen Y, Li E, Yi M, Yang J.The risk and survival outcome of subsequent primary colorectal cancer:cases from 1973 to 2012.BMC Cancer. 2017 ,22;17(1):783 (SCI，IF：3,288)

15. Mao X, Li P, Wang Y ,Yang J*.CRB3 regulates contact inhibition by activating the Hippo pathway in mammary epithelial cells. Cell Death Dis. 2017,12;8(1):e2546.

16. Liu J, Li J, Li P, Wang Y, Liang Z, Jiang Y, Li J, Feng C, Wang R, Chen H, Zhou C, Zhang J, Yang J, Liu P. Loss of DLG5 promotes breast cancer malignancy by inhibiting the Hippo signaling pathway. Sci Rep. 2017 Feb 7;7:42125.

17. Lv Meng, Li Shuting, Luo changqin, Yang J* Angiomotin promotes renal epithelial and carcinoma cell proliferation by retaining the nuclear YAP. Oncotarget. 2016 ,15;7(11):12393-403.

18. Yang J, Li S, Wang B, Wu Y, Chen Z, Lv M, Lin Y, Yang J*. Potential biomarkers for anti-EGFR therapy in metastatic colorectal cancer. Tumor Biol. 2016,37(9),11645-11655.

19. Li D, Du XL, Ren Y, Yang J* Comparative Analysis of Clinicopathologic Features of, Treatment in, and Survival of Americans with Lung or Bronchial Cancer.PLoS One. 2016 ,31;11(5):e0156617.

20. Yang J, Du XL, Li ST, et al. Characteristics of Differently Located Colorectal Cancers Support Proximal and Distal Classification: A Population-Based Study of 57,847 Patients.PLoS One. 2016 9;11(12):e0167540.

21. Shen YW, Zhang XM, li ST, Yang J*. Efficacy and safety of icotinib as first-line therapy in patients with advanced non-small-cell lung cancer. Oncotargets and Therapy, 2016:9 929–935.

22. Chen ZL, Shen YW, Li ST, Yang J*.The efficiency and safety of trastuzumab and lapatinib added to neoadjuvant chemotherapy in Her2-positive breast cancer patients: a randomized meta-analysis. Onco Targets Ther. 2016 ,30;9:3233-47.

23. Primary primitive neuroectodermal tumor in pelvicavity: an unnsual case and literature report. Int J Clin Exp Med, 2016;9(2):4767-4774.

24. Wang X, Shen Y, Li S, Lv M, Zhang X, Yang J, Wang F, Yang J*. Importance of the interaction between immune cells and tumor vasculature mediated by thalidomide in cancer treatment (Review).Int J Mol Med. 2016; 38(4):1021-1029.

25. Lv M, Chen L, Qin T, Zhang X, Liu P, Yang J*. Angiomotin promotes breast cancer cell proliferation and invasion. Oncol Rep. 2015; 33(4):1938-1946.

26. Mao X, Li P, Ren Y, Yang J*.Cell polarity protein CRB3 is an independent favorable prognostic factor for clear cell renal cell carcinoma. Int J Oncol. 2015;46(2):657-666.

27. Yan-Wei shen, Xiao-Man Zhang,Meng lv,ling chen,Tian-Jie Qin,Fan Wang,Jiao Yang,Pei-Jun liu,Yang J*. Utility of ganadotropin-releasing hormone agonists for prevention of chemotherapy-induced ovarian damage in premenopausal women with breast cancer: a systematic review and meta analysis. oncoTargets and therapy 2015;83349-3359.

28. Shen YW, Sui YX, Zhang XM.,Yang J* Ipsilateral breast metastasis from a pulmonary adenocarcinoma: a case report and a focused review of the literature. Int J Clin Exp Pathol. 2015; 8(8): 9647–9654.

29. Li J, Liu J, Yang J*, et al. Loss of LKB1 disrupts breast epithelial cell polarity and promotes breast cancer metastasis and invasion. Journal of Experimental & Clinical Cancer Research 2014, 33(1):70.

30. Juan Yang, Jin Yang, Yan Gao,et al. Identification of potential serum proteomic biomarkers for clear cell renal cell carcinoma. PLoS One. 2014; 9(11):e111364.

31. Jin Yang, Peijun Liu, Meijuan Tian, et,al. Proteomic identification of angiomotin by ProteomeLab PF-2D and correlation with clinical outcome in human clear cell renal cell carcinoma. Int J Oncol.2013; 42(6):2078-2086.

32. Jin Yang, Yucong Yang, Xu Li. Identification of Cyclophilin A as a Potential Prognostic Factor for clear-cell Renal Cell Carcinoma by Comparative Proteomic Analysis. Cancer Biology and Therapy. 2011, 11(5),535-546.

33. Tingting Cheng, Lina Wang, Yuyao Li, Jin Yang* et al. Differential microRNA expression in renal cell carcinoma. Oncology Letter . 2013, 6,769-776.

34. MYi*,JXu, P Liu,G J Chang,XLDu,C-y Hu,Y Song.JHe, Y Ren, Y Wei, J Yang,K K Huntand, X Li.Comparative analysis of lifestyle factors, screening test use, and clinicopathologic features in association with survival among Asian Americans with colorectal cancer. British Journal of Cancer ,2013, 1–7 .

35. P Liu,XLi, E A Mittendorf,JLi,XLDu,JHe, Y Ren, J Yang,K K Hunt, M Yi.Comparison of clinicopathologic features and survival in young American women aged 18–39 years in different ethnic groups with breast cancer. British Journal of Cancer ,2013, 1–8 .

36. Li J, Liu J, Liang Z, He F, Yang L, Li P, Jiang Y, Wang B, Zhou C, Wang Y, Ren Y, Yang J, Zhang J, Luo Z, Vaziri C, Liu P. Simvastatin and Atorvastatin inhibit DNA replication licensing factor MCM7 and effectively suppress RB-deficient tumors growth. Cell Death Dis. 2017 Mar 16;8(3):e2673.

37. Liang Z, Li W, Liu J, Li J, He F, Jiang Y, Yang L, Li P, Wang B, Wang Y, Ren Y, Yang J, Luo Z, Vaziri C, Liu P. Simvastatin suppresses the DNA replication licensing factor MCM7 and inhibits the growth of tamoxifen-resistant breast cancer cells. Sci Rep. 2017 Feb 2;7:41776.

38. Li J, Liu J, Ren Y, Yang J, Liu P. Common Chromosomal Fragile Site Gene WWOX in Metabolic Disorders and Tumors. Int J Biol Sci. 2014 Jan 11;10(2):142-8.